4.7 Review

Controversies and research agenda in nephropathic cystinosis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

期刊

KIDNEY INTERNATIONAL
卷 89, 期 6, 页码 1192-1203

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2016.01.033

关键词

biomarker; cell signaling; chronic kidney disease; cystinosin; end-stage kidney disease; rare kidney diseases

资金

  1. National Institutes of Health
  2. Raptor
  3. Alexion
  4. Hyperion
  5. University of Michigan
  6. Kidney Disease: Improving Global Outcomes (KDIGO)
  7. Cystinose Groep Nederland
  8. Cystinosis Foundation
  9. Cystinosis Research Network
  10. La Asociacion Mexicana de Cistinosis
  11. Orphan Europe
  12. Raptor Pharmaceuticals

向作者/读者索取更多资源

Nephropathic cystinosis is an autosomal recessive metabolic, lifelong disease characterized by lysosomal cystine accumulation throughout the body that commonly presents in infancy with a renal Fanconi syndrome and, if untreated, leads to end-stage kidney disease (ESKD) in the later childhood years. The molecular basis is due to mutations in CTNS, the gene encoding for the lysosomal cystine-proton cotransporter, cystinosin. During adolescence and adulthood, extrarenal manifestations of cystinosis develop and require multidisciplinary care. Despite substantial improvement in prognosis due to cystine-depleting therapy with cysteamine, no cure of the disease is currently available. Kidney Disease: Improving Global Outcomes (KDIGO) convened a Controversies Conference on cystinosis to review the state-of-the-art knowledge and to address areas of controversies in pathophysiology, diagnostics, monitoring, and treatment in different age groups. More importantly, promising areas of investigation that may lead to optimal outcomes for patients afflicted with this lifelong, systemic disease were discussed with a research agenda proposed for the future.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据